Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · July 25, 2022

Befotertinib in Patients With EGFR T790M–Mutated NSCLC Who Progressed After Prior EGFR TKI Therapy

Journal of Thoracic Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Thoracic Oncology
Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label Study
J Thorac Oncol 2022 Jun 18;[EPub Ahead of Print], S Lu, Y Zhang, G Zhang, J Zhou, S Cang, Y Cheng, G Wu, P Cao, D Lv, H Jian, C Chen, X Jin, P Tian, K Wang, G Jiang, G Chen, Q Chen, H Zhao, C Ding, R Guo, G Sun, B Wang, L Jiang, Z Liu, J Fang, J Yang, W Zhuang, Y Liu, J Zhang, Y Pan, J Chen, Q Yu, M Zhao, J Cui, D Li, T Yi, Z Yu, Y Yang, Y Zhang, X Zhi, Y Huang, R Wu, L Chen, A Zang, L Cao, Q Li, X Li, Y Song, D Wang, S Zhang, L Ding, L Zhang, X Yuan, L Yao, Z Shen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading